Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HELP

STRONG SELLREMOVE

Cybin D/B/A Helus Pharma · Healthcare · Canada · $245M · Avg Vol: $6M/d

6
StockRank
Q
28
V
21
M
29
P/E (TTM)
—
ROE
-55.9%
D/E
—
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

This clinical-stage pharmaceutical firm is highly speculative and does not possess the validated, high-utilization manufacturing assets required to benefit from the CDMO pricing power cycle.

COMPANY DESCRIPTION

Cybin Inc. (d/b/a Helus Pharma) is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health disorders. The company leverages proprietary drug delivery systems and novel molecules to create safe and effective treatments for conditions like depression and anxiety. Its pioneering research in psychedelic medicine positions it at the forefront of a nascent but rapidly evolving therapeutic space.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue0000—
EPS-0.94-0.72-1.97-1.71—
Shares49.9M49.9M49.9M49.9M0.0%
Debt5.6M4.0M0.2M0-80.8%
Equity53.7M34.0M206.0M167.4M46.0%
Op CF-31.9M-33.5M-48.6M-71.5M—
Inv CF-0.5M-2.3M4.9M-1.4M—
Fin CF25.2M9.6M179.6M14.3M—
Loading...
PRICE (1Y)+16.2%
3.874.414.945.486.02May 13Jun 4Jun 25
SMA 50SMA 200
Close
$6.02
RSI (14)
78.3
52W High
$9.83
From 52W High
0.6%

SCORE BREAKDOWN

Quality
28
ROIC
-60.3%11.1
ROE
-55.9%15.7
GP/Assets
—N/A
Op. Margin
0.0%40.6
FCF/Assets
-19.1%18.1
Piotroski
212.0
Int. Cover
—N/A
D/E Ratio
—N/A
Current Ratio
13.78x91.7
Value
21
P/E (TTM)
—N/A
EV/EBITDA
-7.3x25.0
P/FCF
—N/A
P/B
133.4x0.4
P/S
—N/A
Div Yield
—N/A
Momentum
29
52W High %
61%27.2
RS 6M
-24%32.4
SMA 50/200
0.81x16.4
EPS Rev 4W
+2.9%89.2
EPS Rev 12W
+2.5%52.7
EPS Improve
+28%39.1
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$245M
P/E (Forward)
-1.6x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HELP are excluded.

TickerCompanyMkt CapStockRankSignal
HELPCybin D/B/A Helus Pharma(you)$245M6STRONG SELL
NGENNervGen Pharma Corp.$244M1STRONG SELL
MISTMilestone Pharmaceuticals Inc.$161M1STRONG SELL
ENGNenGene Therapeutics Inc.$114M8STRONG SELL
MSLESatellos Bioscience Inc.$119M10STRONG SELL
PMNProMIS Neurosciences, Inc.$97M15STRONG SELL
EPRXEupraxia Pharmaceuticals Inc.$425M25SELL
OBI.LOndine Biomedical Inc.$101M20SELL
QNTM.CNQuantum BioPharma Ltd.$45M2STRONG SELL
EDSAEdesa Biotech, Inc.$61M17STRONG SELL

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%

Cybin D/B/A Helus Pharma (HELP) — Stock Score Summary

Cybin D/B/A Helus Pharma (HELP) has a MoatMap StockRank of 6/100 based on Quality (28/100), Value (21/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL. This clinical-stage pharmaceutical firm is highly speculative and does not possess the validated, high-utilization manufacturing assets required to benefit from the CDMO pricing power cycle.

Cybin Inc. (d/b/a Helus Pharma) is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health disorders. The company leverages proprietary drug delivery systems and novel molecules to create safe and effective treatments for conditions like depression and anxiety. Its pioneering research in psychedelic medicine positions it at the forefront of a nascent but rapidly evolving therapeutic space.

Key Financial Metrics

Price$6.02
Market Cap$245M
P/E (Forward)-1.61
Price/Book133.43
Return on Equity-55.9%
Return on Invested Capital-60.3%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-49M

Cybin D/B/A Helus Pharma operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Cybin D/B/A Helus Pharma’s (HELP) StockRank?
MoatMap’s StockRank for Cybin D/B/A Helus Pharma (HELP) is 6/100, with a Strong Sell signal. It is a composite of Quality (28), Value (21), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Cybin D/B/A Helus Pharma have an economic moat?
Cybin D/B/A Helus Pharma (HELP) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cybin D/B/A Helus Pharma a buy, hold, or sell?
MoatMap’s current signal for Cybin D/B/A Helus Pharma (HELP) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cybin D/B/A Helus Pharma in?
Cybin D/B/A Helus Pharma (HELP) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).
Browse all ranked stocksHELP deep dive reportAI ChampionsHow we score stocksSense-check another stock